Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

By J. Seidel, A. Otsuka, K. Kabashima. Frontiers in Oncology, 2018

1,158 citations recorded by the source corpus.

Melanoma, a skin cancer associated with high mortality rates, is highly radio- and chemotherapy resistant but can also be very immunogenic. These circumstances have led to a recent surge in research into therapies aiming to boost anti-tumor immune responses in cancer patients. Among these immunotherapies, neutralizing antibodies targeting the immune checkpoints T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) are being hailed as particularly successful. These antibodies have resulted in dramatic improvements in disease outcome and are now clinically approved in many countries. However, the majority of advanced stage melanoma patients do not respond or will relapse, and the hunt for the “magic bullet” to treat the disease continues. This review examines the mechanisms of action and the limitations of anti-PD-1/PD-L1 and anti-CTLA-4 antibodies which are the two types of checkpoint inhibitors currently available to patients and further explores the future avenues of their use in melanoma and other cancers.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/af3cf98b70dccd06ae4124f3640d1d2712761f62

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Y. Shiravand
R. Ladwa
K. O'Byrne
S. R. Hosseini-Fard
Faezeh Khodadadi
Seyyed Mohammad Amin Kashani
H. Sadeghirad
Shadi Hosseini

Citations in the corpus

Immune Checkpoint Inhibitors in Cancer Therapy (2022, background): “Antibodies targeting immune inhibitory receptors, such as CTLA-4, PD-1, and PD-L have been the most widely used immunotherapeutic agents in the last decade [4].”